Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma

Fig. 3

MAPK7 amplification correlates with protein expression and drives proliferation in tumor cell lines KYSE30 and SNU449. a Representative FISH images of the MAPK7 amplified cell lines KYSE30 and SNU449, and the MAPK7 diploid line, H1793. FISH probes were generated for MAPK7 (red) and internal CEP17 control (green) genes. b Western blot MAPK7 protein expression analysis of cell lines following 4 day treatment with siRNA controls (left 3 lanes in each panel) or MAPK7-directed siRNAs (right 3 lanes in each panel). GAPDH is included as a protein loading control. c 4 days post-siRNA transfection, tumor cell lines were assessed for cell survival using an Acumen platform and utilizing ‘live/dead’ cell stains (for details see ‘Methods’). d Following siRNA transfection, cell growth dynamics were captured over a 6 day period in all treatment groups using an Incucyte cell confluence imaging platform. Treatment groups are represented by colored lines as follows: Light blue – No SiRNA, Dark blue – NC Dharmacon, Red – NC Qiagen, Purple – MAPK7si2, Gold – MAPK7si4, Turquoise – MAPK7si5

Back to article page